Here’s Why Bluebird Bio (BLUE) Stock Shot Up 43% After-Hours

December 9, 2014 12:42 PM

14 0

Bluebird shares soared 43% in extended trading yesterday after the company reported encouraging trial results for its experimental gene therapy for patients with beta-thalassemia

Bluebird bio Inc (NASDAQ:BLUE) saw its share price explode in yesterday's extended trading session, rising by as much as 43% to reach $70 apiece, after the company announced that its experimental gene therapy, LentiGlobin BB305, had helped treat patients suffering from an inherited blood disorder wi...

Read more

To category page